Effects of Varenicline, Bupropion, Nicotine Patch, and Placebo on Treating Smoking Among Persons With Current or Past Major Depressive Disorder: Secondary Analysis of a Double-Blind, Randomized, Placebo-Controlled Trial
All medications were generally safe in both MDD cohorts. NRT and bupropion were not more effective than placebo for those with current MDD. Varenicline plus counseling may be the best treatment for individuals with past or current MDD, given its greater efficacy, similar risk of adverse events, and, for those with current depression, reductions in anxiety and depression while trying to quit smoking.
Authors
- Maher Karam‐Hage (ORCID: https://orcid.org/0000-0001-5883-4436)
- Robert M. Anthenelli (ORCID: https://orcid.org/0000-0002-6612-1126)
- Jennifer A. Minnix (ORCID: https://orcid.org/0000-0001-6017-6735)
- Paul M. Cinciripini (ORCID: https://orcid.org/0000-0003-2877-9928)
- Janice A. Blalock (ORCID: https://orcid.org/0000-0003-2893-0245)
- David Lawrence
- George Kypriotakis (ORCID: https://orcid.org/0000-0002-2011-4545)
- Chad D. Morris (ORCID: https://orcid.org/0000-0002-8498-8647)
- Diane Beneventi (ORCID: https://orcid.org/0000-0002-6568-3231)
- Charles E. Green
Institutions
- Pfizer (United States) (US)
- University of California San Diego (US)
- The University of Texas Health Science Center at Houston (US)
Publication Details
- Journal
- American Journal of Psychiatry
- Published
- 2024-12-11
- DOI
- https://doi.org/10.1176/appi.ajp.20230855
- Citations
- 4
- Primary Topic
- Smoking Behavior and Cessation
- Type
- article
- Field-Weighted Citation Impact
- 1.31